Live Analyst Rating Changes 24636 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Julian Harrison
BTIG

Julian Harrison

Wall Street Analyst
★★☆☆☆
#2655
on 13Foresight · ranked by our own returns
48%
Success Rate
+10.0%
Average Return
36 of 75 calls profitable · +4.5% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 48% of Julian Harrison's ratings turned a profit when each position was held for 1 year — averaging +10.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

172 Buy 7 Hold 0 Sell
Julian's Stock Coverage 38 ratings · 2026-08-14
Company Date Position Consensus Price Target 1-Yr Return vs S&P 500
LQDA
Liquidia Technologies
Aug 12, 2026 BUY Strong Buy
-0.8% avg upside
15 analysts
$111.00
54.01% Upside
-5.5% ·
CNTB
Connect Biopharma Holdings
Aug 12, 2026 BUY Strong Buy
+157.7% avg upside
12 analysts
$10.00
293.67% Upside
· ·
MAZE
Maze Therapeutics, Inc.
Aug 11, 2026 BUY Strong Buy
+128.1% avg upside
12 analysts
$46.00
66.19% Upside
-1.3% ·
SYRE
Spyre Therapeutics
Aug 11, 2026 BUY Strong Buy
-6.0% avg upside
23 analysts
$132.00
29.54% Upside
+0.9% ·
MLTX
MoonLake Immunotherapeutics
Aug 10, 2026 BUY Strong Buy
+78.6% avg upside
20 analysts
$30.00
81.73% Upside
-5.0% ·
JBIO
Jade Biosciences
Aug 10, 2026 BUY Strong Buy
+139.6% avg upside
16 analysts
$77.00
223.42% Upside
+13.7% ·
ORKA
Oruka Therapeutics
Aug 10, 2026 BUY Strong Buy
+16.8% avg upside
16 analysts
$151.00
39.62% Upside
-0.4% ·
AKBA
Akebia Therapeutics
Aug 06, 2026 BUY Strong Buy
+978.8% avg upside
16 analysts
$4.00
359.93% Upside
-6.3% ·
CLYM
Climb Bio
Aug 06, 2026 BUY Strong Buy
+29.3% avg upside
19 analysts
$20.00
35.84% Upside
+16.6% ·
RNAC
Cartesian Therapeutics
Aug 06, 2026 BUY Strong Buy
+261.7% avg upside
19 analysts
$44.00
404.60% Upside
+1.0% ·
AVTX
Avalo Therapeutics
Aug 06, 2026 BUY Strong Buy
+168.6% avg upside
20 analysts
$58.00
198.20% Upside
+4.8% ·
INVA
Innoviva
Aug 05, 2026 BUY Buy
+38.5% avg upside
12 analysts
$42.00
102.32% Upside
+3.3% ·
YARW
Yarrow Bioscience
Aug 03, 2026 BUY Strong Buy
-35.5% avg upside
9 analysts
$58.00
35.71% Upside
+27.3% ·
CGEM
Cullinan Management
Jul 29, 2026 BUY Strong Buy
+73.8% avg upside
15 analysts
$39.00
98.58% Upside
+18.2% ·
OTLK
Outlook Therapeutics
Jul 27, 2026 BUY Buy
+932.2% avg upside
11 analysts
$4.00
350.09% Upside
-16.5% ·
NKTR
Nektar Therapeutics
Jul 13, 2026 BUY Buy
-1.3% avg upside
26 analysts
$178.00
134.54% Upside
+11.3% ·
TVRD
Tvardi Therapeutics
Jul 07, 2026 BUY Buy
+926.8% avg upside
23 analysts
$15.00
747.43% Upside
-42.9% ·
ABVX
Abivax SA Sponsored ADR
Jun 30, 2026 BUY Strong Buy
+10.5% avg upside
15 analysts
$175.00
44.06% Upside
-10.7% ·
TBPH
Theravance Biopharma
Jun 29, 2026 HOLD Buy
+9.0% avg upside
18 analysts
-0.5% ·
APGE
Apogee Therapeutics
Jun 19, 2026 BUY Buy
-5.3% avg upside
19 analysts
$137.00
1.87% Upside
+1.5% ·
RZLT
Rezolute
Jun 02, 2026 BUY Strong Buy
+127.7% avg upside
13 analysts
$6.00
30.42% Upside
+15.0% ·
MREO
Mereo Biopharma Group Plc
Mar 19, 2026 BUY Strong Buy
+1190.6% avg upside
11 analysts
$1.00
224.95% Upside
-11.1% ·
UTHR
United Therapeutics
Feb 25, 2026 HOLD Buy
-14.2% avg upside
26 analysts
-6.6% ·
ARDX
Ardelyx
Feb 20, 2026 BUY Strong Buy
+243.9% avg upside
21 analysts
$17.00
334.77% Upside
-29.1% ·
VRDN
Viridian Therapeutics
Nov 04, 2025 BUY Strong Buy
+59.8% avg upside
32 analysts
$61.00
177.43% Upside
-2.1% ·
PTGX
Protagonist Therapeutics
Nov 03, 2025 BUY Strong Buy
-23.0% avg upside
19 analysts
$82.00
45.78% Downside
+104.2% ·
RANI
Rani Therapeutics Holdings
Mar 31, 2025 BUY Strong Buy
+1090.9% avg upside
10 analysts
$14.00
1654.62% Upside
-41.3% ·
ZLDPF
Zealand Pharma
Mar 17, 2025 BUY Buy
+57.2% avg upside
11 analysts
$161.87
207.19% Upside
-51.5% ·
KROS
Keros Therapeutics
Dec 12, 2024 HOLD Strong Buy
+123.3% avg upside
21 analysts
+16.7% ·
ANAB
AnaptysBio
Dec 02, 2024 HOLD Strong Buy
+29.2% avg upside
26 analysts
+67.8% ·
ACRS
Aclaris Therapeutics
Nov 18, 2024 BUY Strong Buy
+70.1% avg upside
15 analysts
$8.00
36.57% Upside
-20.7% ·
AURA
Aura Biosciences Inc
Nov 13, 2024 BUY Strong Buy
+164.4% avg upside
9 analysts
$24.00
213.68% Upside
-46.5% ·
MTNB
Matinas BioPharma
Nov 09, 2023 BUY Buy
+5844.2% avg upside
7 analysts
$50.00
21359.27% Upside
-94.2% ·
BIORQ
Biora Therapeutics
May 03, 2022 BUY Buy
+269249900.0% avg upside
6 analysts
$4.00
3999900.01% Upside
· ·
VKTX
Viking Therapeutics
Apr 28, 2021 BUY Strong Buy
+117.8% avg upside
31 analysts
$12.00
63.58% Downside
-62.0% ·
ALDX
Aldeyra Therapeutics
Apr 27, 2021 BUY Strong Buy
+1006.4% avg upside
21 analysts
$29.00
1913.89% Upside
-77.3% ·
PLRX
Pliant Therapeutics
Apr 20, 2021 BUY Buy
+1960.5% avg upside
21 analysts
$51.00
4622.12% Upside
· ·
WHWK
Whitehawk Therapeutics
Dec 09, 2020 BUY Buy
+166.3% avg upside
14 analysts
$60.00
1182.14% Upside
-27.5% ·
🔒 33 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Julian Harrison — Frequently Asked Questions
How accurate are Julian Harrison's stock ratings?
Based on the calls 13Foresight could measure, about 45% of Julian's ratings were profitable over a one-year hold, with an average return of +9.3% per rating, or +4.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Julian ranked on 13Foresight?
Julian Harrison is currently ranked #2655 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Julian cover?
Julian most recently has ratings on LQDA, CNTB, MAZE, SYRE, MLTX, JBIO, ORKA, AKBA, CLYM, RNAC, AVTX, INVA and 26 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.